These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34720085)

  • 1. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.
    Lee DD; Komosa M; Sudhaman S; Leão R; Zhang CH; Apolonio JD; Hermanns T; Wild PJ; Klocker H; Nassiri F; Zadeh G; Diplas BH; Yan H; Gallinger S; Pugh TJ; Ramaswamy V; Taylor MD; Castelo-Branco P; Nunes NM; Tabori U
    J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
    Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
    J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers.
    Rowland TJ; Bonham AJ; Cech TR
    Mol Oncol; 2020 Oct; 14(10):2358-2374. PubMed ID: 33245585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers.
    Esopi D; Graham MK; Brosnan-Cashman JA; Meyers J; Vaghasia A; Gupta A; Kumar B; Haffner MC; Heaphy CM; De Marzo AM; Meeker AK; Nelson WG; Wheelan SJ; Yegnasubramanian S
    Cell Oncol (Dordr); 2020 Oct; 43(5):847-861. PubMed ID: 32468444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
    Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
    Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
    Castelo-Branco P; Leão R; Lipman T; Campbell B; Lee D; Price A; Zhang C; Heidari A; Stephens D; Boerno S; Coelho H; Gomes A; Domingos C; Apolonio JD; Schäfer G; Bristow RG; Schweiger MR; Hamilton R; Zlotta A; Figueiredo A; Klocker H; Sültmann H; Tabori U
    Oncotarget; 2016 Sep; 7(36):57726-57736. PubMed ID: 27437772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
    Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
    Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer.
    Faleiro I; Apolónio JD; Price AJ; De Mello RA; Roberto VP; Tabori U; Castelo-Branco P
    Future Oncol; 2017 Oct; 13(23):2045-2051. PubMed ID: 29019414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
    Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
    Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
    McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
    Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
    [No Abstract]   [Full Text] [Related]  

  • 11. DNA methylation of the TERT promoter and its impact on human cancer.
    Lee DD; Komosa M; Nunes NM; Tabori U
    Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Liu L; Liu C; Fotouhi O; Fan Y; Wang K; Xia C; Shi B; Zhang G; Wang K; Kong F; Larsson C; Hu S; Xu D
    Oncologist; 2017 Oct; 22(10):1178-1188. PubMed ID: 28754720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting oncogenic TERT promoter variants by allele-specific epigenome editing.
    Kouroukli AG; Rajaram N; Bashtrykov P; Kretzmer H; Siebert R; Jeltsch A; Bens S
    Clin Epigenetics; 2023 Nov; 15(1):183. PubMed ID: 37993930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allele-Specific DNA Methylation and Its Interplay with Repressive Histone Marks at Promoter-Mutant TERT Genes.
    Stern JL; Paucek RD; Huang FW; Ghandi M; Nwumeh R; Costello JC; Cech TR
    Cell Rep; 2017 Dec; 21(13):3700-3707. PubMed ID: 29281820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines.
    McKelvey BA; Zeiger MA; Umbricht CB
    Mol Oncol; 2020 Oct; 14(10):2355-2357. PubMed ID: 32920953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
    Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
    Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations and telomeres during tumorigenesis.
    Lorbeer FK; Hockemeyer D
    Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. THOR is a targetable epigenetic biomarker with clinical implications in breast cancer.
    Apolónio JD; Dias JS; Fernandes MT; Komosa M; Lipman T; Zhang CH; Leão R; Lee D; Nunes NM; Maia AT; Morera JL; Vicioso L; Tabori U; Castelo-Branco P
    Clin Epigenetics; 2022 Dec; 14(1):178. PubMed ID: 36529814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing.
    Gupta S; Vanderbilt CM; Lin YT; Benhamida JK; Jungbluth AA; Rana S; Momeni-Boroujeni A; Chang JC; Mcfarlane T; Salazar P; Mullaney K; Middha S; Zehir A; Gopalan A; Bale TA; Ganly I; Arcila ME; Benayed R; Berger MF; Ladanyi M; Dogan S
    J Mol Diagn; 2021 Feb; 23(2):253-263. PubMed ID: 33285287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
    Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
    Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.